Análisis del impacto presupuestario de incorporar alemtuzumab para el tratamiento de la esclerosis múltiple a recaídas y remisiones en Argentina

Abstract

The objective of the study was to estimate the budget impact of incorporating alemtuzumab to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) in Argentina, from the perspective of social security.

Methods

A budget impact model was used. A time horizon of 3 years was considered. The target population was determined based on RRMS prevalence and incidence data published in Argentina. All treatment options for RRMS used in Argentina were considered as comparators. The costs of pharmacological treatments, administration and monitoring were used. For medicines, the laboratory starting price (PSL) was estimated based on information from the Pharmaceutical Manual (AlfaBeta). Administration and monitoring costs were obtained from national Social Security. Market shares and their evolution were prepared based on the opinion of local experts and market research. The results are reported in terms of annual, percentage and total cumulative budget impact.

Results

Incorporating alemtuzumab as a therapeutic option showed a budget impact of $1,393 million (2.98%), $92 million (0.19%) and −$1,858 million (−3.9%), in years 1 to 3, respectively. The result considers a retreatment rate with alemtuzumab of 98% for the second year and 26% for the third year. The cumulative budget impact over 3 years showed a savings of $373 million (−0.73% compared to the scenario without alemtuzumab).

Conclusion

The study shows that, according to the assumptions considered, the cumulative budget impact in 3 years of incorporating alemtuzumab as a therapeutic option for adult patients with RRMS in Argentina would be cost-saving.